Amneal Pharmaceuticals, Inc. Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc.

AMRX

Hisse Senetlerindeki Sıralama #3013
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is... Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Hisse Fiyatı
$19.07
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$6.09B
Değişim (1 gün)
-0.94%
Değişim (1 yıl)
92.24%
Ülke
US
Ticaret Amneal Pharmaceuticals, Inc. (AMRX)

Kategori

Healthcare
Amneal Pharmaceuticals, Inc. (AMRX) için Faaliyet Marjı
October 2026 itibarıyla Faaliyet Marjı TTM: 12.93%
Amneal Pharmaceuticals, Inc. şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) 12.93%'dir. 2023 yılı sonunda şirketin faaliyet marjı 8.54% idi.
Amneal Pharmaceuticals, Inc. için 2014 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
Yıl Faaliyet Marjı Değiştir
2026 (TTM) 12.93% 44.96%
2024 8.92% 4.45%
2023 8.54% -299.07%
2022 -4.29% -158.85%
2021 7.29% 59.52%
2020 4.57% -154.08%
2019 -8.45% 616.10%
2018 -1.18% -104.98%
2017 23.71% -15.26%
2016 27.98% 6.67%
2015 26.23% -7.58%
2014 28.38% 0.00%
Benzer şirketler veya rakipler için Faaliyet Marjı
Şirket Faaliyet Marjı Faaliyet Marjı Farkı Ülke
0.00% -
DE
0.00% -
DE
0.00% -
JP
0.00% -
CH
22.93% -98.23%
IN
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.